SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is gaining significant attention following its announcement of $10 million in new orders for autonomous systems, including counter-UAS and robotic ground solutions, signaling a strong demand in global defense and security. The community is buzzing with bullish sentiment, anticipating further growth as recent FCC actions against foreign drone imports create a compelling market opportunity for domestic manufacturers like Ondas, with many discussing a potential short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is actively trending following the FDA approval of NEREUS, marking the first new motion sickness treatment in over 40 years. The community is highly focused on NEREUS's potential to address GLP-1 induced nausea, seeing this as a massive market opportunity and positioning VNDA as a compelling buyout target for larger pharmaceutical companies. This significant regulatory win, alongside a strong pipeline, is driving optimism for substantial future upside.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending with high volatility, driven by its exceptionally low public float and significant insider ownership. The community is actively discussing its potential for a short squeeze, frequently drawing comparisons to other recent low-float SPACs that experienced rapid price surges. Sentiment remains bullish, fueled by speculation that its tight share structure could lead to further dramatic moves.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a surge in conversation after significant insider buying, including notable purchases by CEO Elliott Hill and Apple CEO Tim Cook, signaled strong confidence in the company's prospects. This has sparked widespread bullish sentiment about a potential turnaround and a possible short squeeze, though some remain cautious, highlighting ongoing market challenges and competition.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following the FDA's Complete Response Letter for its relacorilant drug, which cited a need for more efficacy evidence despite the GRACE trial meeting its primary endpoint. This news has sparked a polarized debate, with many investors viewing the substantial stock drop as an overreaction and a prime "bargain biobuy" given the company's strong existing revenue and extensive pipeline. However, others remain cautious, calling it a "total reset" while some attribute parts of the decline to typical end-of-year tax-loss selling.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as year-end tax loss selling and broader crypto market sentiment fuel a sharp divide among holders. The community actively debates whether current levels present a buying opportunity for a future rally or if further declines are imminent, reflecting a mix of long-term conviction and short-term volatility concerns.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is trending amidst significant market volatility following repeated increases in margin requirements by the CME Group for precious metal futures. This has sparked intense debate, with many asserting that these actions are an attempt to suppress price discovery and protect short positions against strong industrial demand and potential global supply shifts, while others view the recent rally as unsustainable. The community is sharply divided between those accumulating on dips, expecting a substantial long-term rise, and those predicting a significant correction.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant momentum following FDA updates, notably the acceptance with priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation. The community is highly optimistic, celebrating current gains and actively discussing the substantial long-term potential of its pipeline, especially as positive pre-NDA feedback was also received for AXS-12 in narcolepsy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco S&P MidCap Momentum ETF (XMMO) Be on Your Investing Radar?

Court Ruling Lifts Markets: High Beta, Momentum ETFs in Focus

Kyndryl Holdings (KD) shares plunged as much as 12% on Thursday after short-seller Gotham City Research accused the IT services provider of accounting manipulation, claiming the stock is significantly overvalued and could drop by as much as 67% or even to zero.In a <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gothamcityresearch.com/post/kyndryl-like-the-old-ibm-except-with-an-undisclosed-cost-problem-part-i">report</a> titled ‘Like the old IBM, except with an Undisclosed Cost Problem: Part I,’ Gotham alleged that Kyndryl has misrepresented its financial health by inflating adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) and adjusted free cash flow to create “the illusion of profitability.”Kyndryl, which spun off from IBM in 2021, has benefited from special pricing arrangements with its former parent, according to Gotham.&nbsp;The short-seller highlighted that Kyndryl’s payments to IBM for services totaled around $4 billion in&nbsp;the fiscal&nbsp;year 2021, roughly 25% of its total cost of services. By fiscal&nbsp;year 2023, those payments had declined 60% to $1.4 billion.Gotham argues that&nbsp;cost reductions, rather than operational improvements, are behind Kyndryl’s post-spinoff margin expansion.&nbsp;IBM’s stock&nbsp;traded in the red on Thursday morning, edging lower by 0.5%.The report further warned that these favorable terms are set to expire, predicting a sharp increase in IBM service costs in 2025 and 2026 that could weigh on earnings.CEO Martin Schroeter has downplayed cost pressures in the past, but Gotham estimates Kyndryl faces an additional $1 billion to $2 billion in expenses over the coming years.Another red flag, according to the report, is Kyndryl’s decision to stop disclosing IBM-related costs after fiscal 2023. Gotham suggests this omission may indicate the company is bracing for significantly higher expenses that could challenge its growth narrative.Gotham’s report also raised broader concerns about Kyndryl’s financial reporting. It identified discrepancies in the company’s reported payments to IBM between 2019 and 2023 and flagged a suspiciously stable $1.38 billion in related-party service costs across multiple reporting periods.The company also pointed to Kyndryl’s capitalized costs, which it says are 13.6 times higher than those of industry peers. Adjusted EBITDA, Gotham estimates, would be 61% to 72% lower if Kyndryl applied industry-standard accounting practices.Additionally, the report questioned Kyndryl’s reported cash flows, highlighting an unusually low days sales outstanding (DSO) of 34 days, which is well below the peer average of 80 days, according to the company.Gotham suggested that Kyndryl may be relying on receivables factoring to inflate its cash position artificially.The short-seller also cast doubt on Kyndryl’s “Total Signings” metric, which has increased from $13.5 billion in&nbsp;the fiscal&nbsp;year 2021 to $16.3 billion in 2024, despite declining total revenue.A recently disclosed Critical Audit Matter in Kyndryl’s 2024 10-K added to concerns, with the company’s auditor stating it did not maintain “effective internal control over financial reporting” as of March 31, 2024.Gotham also noted that 50% of Kyndryl’s management compensation is tied to “Adjusted Operating Cash Flow,” a metric the company has not disclosed since 2021.It flagged that insider selling has also increased&nbsp;recently, further fueling concerns.Gotham concluded that Kyndryl’s stock remains “uninvestable” due to these concerns.<figure class="image"><img style="aspect-ratio:1294/302;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_093222_png_d52e5d9a2b.webp" alt="Screenshot 2025-03-27 093222.png" width="1294" height="302"><figcaption>Kyndryl retail sentiment and message volume on March 27 as of 9:35 a.m. ET | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KD">Kyndryl’s stock</a>&nbsp;jumped to ‘extremely bullish’ territory.Some investors dismissed the accusations, with one user stating they plan to hold onto their shares.<stembedurl>https://stocktwits.com/tothattila/message/609420502</stembedurl>Another expects a slow recovery through to May, followed by a jump when earnings happen.<stembedurl>https://stocktwits.com/tothattila/message/609431999</stembedurl>The allegations overshadowed Kyndryl’s announcement of an expanded partnership with Google Cloud.&nbsp;The collaboration includes a new Mainframe Modernization with Gen AI Accelerator Program, leveraging Google’s Gemini models to enhance mainframe integration, COBOL-to-Java conversion, and AI training using on-premise data.Kyndryl’s stock has fallen 14% in 2025 but remains up nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-slides-pre-market-after-jefferies-downgrades-stock-citing-nvidia-dominance-intel-competition-retail-sentiment-sours/chJ22OkRbEd">AMD Slides Pre-Market After Jefferies Downgrades Stock Citing Nvidia Dominance, Intel Competition – Retail Sentiment Sours</a>

Information technology infrastructure provider Kyndryl (USA) booth at Tokyo Rainbow Parade 2023. (Photo by Stanislav Kogiku/SOPA Images/LightRocket via Getty Images)

Kyndryl Stock Sinks After Short-Seller Alleges IBM Deal Masked Billions In Hidden Costs – But Retail Traders Aren’t Buying It

Short-seller Gotham City Research calls Kyndryl ‘uninvestable,’ raising concerns over its financial reporting, cash flows, and insider selling.

Equity

ESAB Corp (ESAB) stock fell about 2.7% over the past week, but Evercore ISI upgraded the stock to ‘In Line’ from ‘Underperform.’According to The Fly, Evercore analyst David Raso set a price target of $120, compared to the earlier price target of $122. The new price target was roughly the same as the stock’s last closing price.The company had forecast 2025 core adjusted earnings between $5.10 and $5.25 per share, compared with Wall Street’s estimate of $5.38 per share last week.Evercore said that while it has trimmed the price, its analysis "suggests enough cushion is baked into ESAB's guide."The analyst said that recent stock weakness, along with ‘a few elements that could break its way to render the guide particularly conservative.’ESAB had forecast total core sales growth to be between flat and a negative 2% in 2025.The company’s fourth-quarter sales had fallen 3% to $671 million.The company, whose products are used in welding and gas control, had said its total sales in the Americas segment had declined 8%, hurt by the strengthening of the U.S. dollar compared to other currencies in the region.The company expects foreign currency-related challenges to dent its sales in 2025 as well.According to FinChat data, ESAB's forward price-to-earnings (PE) ratio is 24.1.The PE ratio gauges a company's profitability. &nbsp;Retail sentiment on Stocktwits remained in the ‘bullish’ (58/100) territory, while retail chatter was ‘normal.’<figure class="image"><img style="aspect-ratio:801/179;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ESAB_Feb_24_6dd3a5fda8.JPG" alt="ESAB’s Sentiment Meter and Message Volume as of 01:17 a.m. ET on Feb. 24, 2025 | Source: Stocktwits" width="801" height="179"><figcaption>ESAB’s Sentiment Meter and Message Volume as of 01:17 a.m. ET on Feb. 24, 2025 | Source: Stocktwits</figcaption></figure>Over the past year, <a href="https://stocktwits.com/symbol/ESAB">ESAB stock </a>has gained 29.8%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/diamondback-energy-q4-earnings-preview-lower-oil-prices-to-dent-bottom-line-retail-remains-extremely-bullish/chdPZaYRxb">Diamondback Energy Q4 Earnings Preview: Lower Oil Prices To Dent Bottom Line, Retail Remains Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ESAB company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

ESAB Stock Receives Evercore Upgrade After Recent Selloff, Retail Stays Bullish 

According to The Fly, Evercore analyst David Raso set a price target of $120, compared to the earlier price target of $122.

Light &amp; Wonder Inc. (LNW) stock rose 4.06% in after-hours trading on Tuesday as the company agreed to acquire the charitable gaming assets of Grover Gaming Inc. and G2 Gaming Inc. for $850 million in cash, but retail sentiment slipped.Under the agreement, Light &amp; Wonder will pay a four-year revenue-based earn-out of up to $200 million cash. The purchase price amounts to a 7.7x multiple based on Grover’s 2024 adjusted earnings before interest, taxes, depreciation, and amortization.Grover Charitable Gaming, which has “long-standing” relationships with charitable customers in the states where it operates, reported revenue of $135 million and adjusted EBITDA of $111 million for the year ended December 31, 2024.The transaction is expected to close during the second quarter of 2025. Light &amp; Wonder plans to fund the acquisition with existing cash and incremental debt financing.“Grover Gaming is a leading player in charitable gaming, a category that has experienced significant growth in recent years,” said Matt Wilson, President and CEO of Light &amp; Wonder. “This transaction complements our position as the leading cross-platform global games company by adding another compelling regulated adjacency to our profile.”The deal also complements Light &amp; Wonder’s cross-platform strategy in addition to being highly accretive to “value and earnings with high-single digit” adjusted net operating profit after tax per share accretion in the first full calendar year after the acquisition, &nbsp;the company said. Sentiment on Stocktwits was ‘bearish’ from ‘ bullish’ a day ago. Message volume was in the ‘low’ zone.<figure class="image"><img style="aspect-ratio:1304/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_19_at_12_45_17_PM_11527e6273.png" alt="Screenshot 2025-02-19 at 12.45.17 PM.png" width="1304" height="320"><figcaption>LNW sentiment meter and message volume on Feb 19 as of 2:30 am ET</figcaption></figure>Light &amp; Wonder, a cross-platform global games company, has over 6,000 members.For its next quarterly earnings, the company is expected to post earnings per share of $0.89 on estimated revenue of $799.17 million, according to Stocktwits data.<a href="https://stocktwits.com/symbol/LNW">Light &amp; Wonder stock</a> is up 17% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

Light & Wonder Stock Jumps After Snapping Up Grover Gaming’s Charitable Assets: Retail Sentiment Lags

The transaction is expected to close during the second quarter of 2025.

Shares of nutrition products company, BellRing Brands Inc., were up 2.89% in after-hours trading on Monday following the company’s better-than-expected first-quarter earnings, with retail sentiment staying strong.BellRing posted $0.58 in earnings per share, beating Wall Street estimates of $0.48. Its revenue stood at $532.9 million, beating estimates of $524.74 million. Its net sales increased by 23.8% compared to the prior year period, driven by a 20.8% increase in volume and a 3% increase in price/mix.For fiscal year 2025, BellRing raised its guidance range for net sales to $2.26 - $2.34 billion and adjusted earnings before interest, taxes, depreciation and amortization (Ebitda) &nbsp;to range between $470-$500 million, translating into net sales and adjusted EBITDA growth of 13%-17% and 7%-14%, respectively, over the fiscal year 2024.BellRing expects fiscal year 2025 capital expenditures of about $7 million.Sentiment on Stocktwits has been ‘extremely bullish’ compared to a week ago. Message volumes climbed to the ‘extremely high’ category.<figure class="image"><img style="aspect-ratio:1294/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_04_at_10_14_33_AM_5d75dd39b9.png" alt="Screenshot 2025-02-04 at 10.14.33 AM.png" width="1294" height="302"><figcaption>BRBR sentiment meter and message volumes on Feb 3</figcaption></figure>“We are pleased with our first quarter performance. Premier Protein consumption accelerated, lifted by distribution gains, strong velocities and incremental promotional activity. The brand achieved new all-time highs for household penetration and total distribution points,” Darcy H. Davenport, president and CEO of BellRing said.“We saw strong margins aided by the timing of marketing spend and non-recurring cost favorability. Our momentum remains high, with the convenient nutrition category continuing to drive robust growth. Our strong start to 2025 gives us greater confidence in the full year and drove our decision to raise our outlook.”During the first quarter, BellRing also repurchased 0.1 million shares for $11 million at an average price of $77.12 per share. As of January 31, 2025, BellRing had $124.1 million remaining under its share repurchase authorization.BellRing’s brands include Premier Protein, a ready-to-drink protein and convenient nutrition brand, and Dymatize, which is a hydrolyzed protein powder supplement.For updates and corrections, email newsroom[at]stocktwits[dot]com

BellRing Brands Stock Up On Q1 Earnings Beat: Retail's Extremely Bullish

BellRing posted $0.58 in earnings per share, beating Wall Street estimates of $0.48. 

XMMO
Invesco S&P MidCap Momentum ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XMMO News

XMMOInvesco S&P MidCap Momentum ETF